by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
by Nicole Kuchinsky | Oct 15, 2015
Last week, a Nature News article reported that the Harvard geneticist George Church had modified over 60 genes in pig embryos using CRISPR/Cas9 gene editing. I’m sure you’re expecting my scientific perspective on the significance of this news in the context of the...
by James Smith | Oct 6, 2015
. With contributions from blogger David Brindley September 2015 has been an historic month for regenerative medicine. For the first time ever in the Western world, a prescription has been issued for a gene therapy, Glybera. At the ESGCT and FSGT Collaborative...
by Hamideh Emrani | Oct 2, 2015
. So many of today’s biomedical advances are only possible because of a step forward in basic science research that happened many years ago. Basic science, be it biology, math or physics, always tries to advance our knowledge of the universe around us. It doesn’t...
by Mark Curtis | Sep 30, 2015
. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...
by Mark Curtis | Sep 29, 2015
. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...
Comments